The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, is being held in Frankfurt, Germany from 8 June to 15 June 2023 in a hybrid format. Myeloma…
Myeloma Patients Europe (MPE) is pleased to announce it has been appointed to the new Health Technology Assessment (HTA) Stakeholder Network of the European Commission. This means that MPE will be actively engaged and consulted…
As part of the Horizon 2020 CARAMBA project, Myeloma Patients Europe (MPE) interviewed experts on different aspects of the CARAMBA clinical trial: manufacturing process, safety updates, and immune monitoring. The videos were filmed during the…
Myeloma Patients Europe (MPE) is pleased to announce that Katie Joyner and Kate Morgan have been appointed as joint Chief Executive Officers (CEO). The MPE Board of Directors unanimously made this decision based on the…
March is Multiple Myeloma Awareness Month. This incurable disease affects increasingly young adult generation. In Europe, more than 50.900 people were diagnosed with myeloma in 2020[1]. Patient organisations from Central and Eastern Europe (CEE)…
One of the MPE Spanish members, the Spanish Amyloidosis Association (AMILO), last month celebrated its fifth anniversary by recognising the support and help other organisations have given them during these five years. MPE is pleased…
THE IMI T2EVOLVE Project and the Horizon 2020 QUALITOP Project have launched a European patient survey on CAR-T treatment. The survey aims to inform on patient and carer experiences and challenges of receiving CAR-T and…
Funding for Daratumumab was recently approved in Israel for the treatment of newly diagnosed multiple myeloma (NDMM) patients in first line treatment, in large part thanks to a strong collaboration between the MPE Israeli member,…